NL-OMON34187已完成不适用
AN OPEN LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF ASP7035 AFTER A SINGLE ORAL DOSE OF 14C-LABELED ASP7035 IN HEALTHY MALE SUBJECTS - ASP7035 MB
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Healthy male
- •- 18 - 55 years of age, inclusive
- •- BMI 18.5 - 30.0 kg/m2
- •- Non-smoker, or not more than 10 cigarettes for at least three months before drug administration
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 12 months prior the start of this study. Participation is also not permitted when participated in more than 3 other drug studies in the 10 months prior to the start of this study.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate how much bempedoic acid is in the body, and the effects and safety of bempedoic acid in children (6 to 17 years of age) with heterozygous familial hypercholesterolemia (a type of high cholesterol) receiving once daily oral dosing.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: LLTClassification code 10054380Term: Familial hypercholesterolemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: LLTClassification code 10057079Term: Heterozygous familial hypercholesterolemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAEUCTR2018-004084-31-DEEsperion Therapeutics, Inc.54
招募中
1 期
A study to evaluate how much bempedoic acid is in the body, and the effects and safety of bempedoic acid in children (6 to 17 years of age) with heterozygous familial hypercholesterolemia (a type of high cholesterol) receiving once daily oral dosing.HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAEUCTR2018-004084-31-NLEsperion Therapeutics, Inc.54
进行中（未招募）
1 期
A study to evaluate how much bempedoic acid is in the body, and the effects and safety of bempedoic acid in children (6 to 17 years of age) with heterozygous familial hypercholesterolemia (a type of high cholesterol) receiving once daily oral dosing.HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAEUCTR2018-004084-31-ESEsperion Therapeutics, Inc.54
招募中
1 期
A study to evaluate how much bempedoic acid is in the body, and the effects and safety of bempedoic acid in children (6 to 17 years of age) with heterozygous familial hypercholesterolemia (a type of high cholesterol) receiving once daily oral dosing.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: LLTClassification code 10054380Term: Familial hypercholesterolemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: LLTClassification code 10057079Term: Heterozygous familial hypercholesterolemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAEUCTR2018-004084-31-DKEsperion Therapeutics, Inc.54
招募中
2 期
An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in Pediatric Patients (6 to 17 Years of Age) with Heterozygous Familial Hypercholesterolemia10027424Heterozygous Familial HypercholesterolemiaFamilial HypercholesterolemiaNL-OMON53717Esperion Therapeutics, Inc.15